earnings largely in line with analyst estimates, bolstering finances in the retail business of the rwep with novo low disk prices continue to be a thorn in the side of novo nordisk, the world's a guest maker of diabetes drugs. the danish pharmaceutical company expects changes in the medicare cap program and weakness in the insulin market to push average prices after rebates lower 2019 over relying ,n demand newer diabetes drugs along with obesity medicine, to counter pricing pressure in the united states. which is a horse its biggest market share, down by 6%. that's a look at european market. vonnie: the dollar has consolidated around the 10 year yield, trading in that range. of orson has been quiet in the summertime. trading has been less frenetic than usual, but we are still at the tube and seven range. interesting action from oil, lower by 3.4%. obviously inventories were lower, but not quite as low as anticipated, causing that reaction. the yuan is trading at 6.829 on that action from the chinese authorities stabilizing the one. , oilomplex is mostly lower inventories really having